148 related articles for article (PubMed ID: 22583430)
1. A brief overview of tyrosine hydroxylase and α-synuclein in the Parkinsonian brain.
Khan W; Priyadarshini M; Zakai HA; Kamal MA; Alam Q
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):456-62. PubMed ID: 22583430
[TBL] [Abstract][Full Text] [Related]
2. Current status of tyrosine hydroxylase in management of Parkinson's disease.
Feve AP
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):450-5. PubMed ID: 22583428
[TBL] [Abstract][Full Text] [Related]
3. A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.
Tabrez S; Jabir NR; Shakil S; Greig NH; Alam Q; Abuzenadah AM; Damanhouri GA; Kamal MA
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):395-409. PubMed ID: 22483313
[TBL] [Abstract][Full Text] [Related]
4. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
5. A role for alpha-synuclein in the regulation of dopamine biosynthesis.
Perez RG; Waymire JC; Lin E; Liu JJ; Guo F; Zigmond MJ
J Neurosci; 2002 Apr; 22(8):3090-9. PubMed ID: 11943812
[TBL] [Abstract][Full Text] [Related]
6. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
7. Targeting Parkinson's - tyrosine hydroxylase and oxidative stress as points of interventions.
Khan MS; Tabrez S; Priyadarshini M; Priyamvada S; Khan MM
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):369-80. PubMed ID: 22483312
[TBL] [Abstract][Full Text] [Related]
8. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
9. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
10. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?
Perez RG; Hastings TG
J Neurochem; 2004 Jun; 89(6):1318-24. PubMed ID: 15189334
[TBL] [Abstract][Full Text] [Related]
11. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
12. Acrolein-mediated alpha-synuclein pathology involvement in the early post-injury pathogenesis of mild blast-induced Parkinsonian neurodegeneration.
Acosta G; Race N; Herr S; Fernandez J; Tang J; Rogers E; Shi R
Mol Cell Neurosci; 2019 Jul; 98():140-154. PubMed ID: 31201929
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of α-synuclein upregulates tyrosine hydroxylase activity in MN9D cells.
Wu B; Liu Q; Duan C; Li Y; Yu S; Chan P; Uéda K; Yang H
Acta Histochem; 2011 Jan; 113(1):32-5. PubMed ID: 19683335
[TBL] [Abstract][Full Text] [Related]
14. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
15. Overview of tyrosine hydroxylase in Parkinson's disease.
Zhu Y; Zhang J; Zeng Y
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):350-8. PubMed ID: 22483316
[TBL] [Abstract][Full Text] [Related]
16. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Locke CJ; Fox SA; Caldwell GA; Caldwell KA
Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411
[TBL] [Abstract][Full Text] [Related]
17. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells.
Pan T; Zhu J; Hwu WJ; Jankovic J
PLoS One; 2012; 7(9):e45183. PubMed ID: 23028833
[TBL] [Abstract][Full Text] [Related]
18. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
19. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
